- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Stanford Study Examines Impact of Frailty and Nutrition on Multiple Myeloma Transplant Outcomes
Research reveals complex relationship between patient health factors and success of autologous stem cell transplantation.
Published on Feb. 27, 2026
Got story updates? Submit your updates here. ›
A new study from Stanford University researchers explores how a multiple myeloma patient's overall health, including frailty and nutritional status, can impact the outcomes of autologous stem cell transplantation (ASCT). The retrospective analysis of 76 patients found that while baseline frailty did not directly correlate with response rates or early toxicity, specific nutritional deficiencies like low BMI were associated with increased risk of infectious complications. The findings underscore the importance of personalized, comprehensive assessment and targeted nutritional interventions to optimize patient resilience and recovery.
Why it matters
As autologous stem cell transplantation remains a critical treatment for multiple myeloma, understanding the complex interplay between a patient's physical condition and transplant outcomes is crucial. This research provides valuable insights that can inform more personalized, holistic approaches to care and help improve long-term survival for myeloma patients.
The details
The Stanford-led study utilized the International Myeloma Working Group's Simplified Frailty Score to categorize 76 myeloma patients as fit, intermediate, frail, or ultra-frail prior to undergoing ASCT in 2024. Researchers also tracked key nutritional biomarkers like BMI, albumin, and neutrophil-to-lymphocyte ratio (NLR) at multiple timepoints. While frailty status alone did not directly predict response or early toxicity, the data showed that a lower baseline BMI was linked to increased risk of infectious complications post-transplant. The team also observed dynamic changes in nutritional markers following ASCT, underscoring the importance of proactive monitoring and support.
- The retrospective analysis focused on 76 multiple myeloma patients who underwent ASCT at a single academic transplant center in 2024.
The players
Angela Zhang
MD, PhD, of Stanford University, who led the research team.
International Myeloma Working Group (IMWG)
The organization that developed the Simplified Frailty Score used in the study to categorize patients.
What’s next
Future research will likely focus on developing predictive models that integrate frailty scores, nutritional biomarkers, and genetic data to better forecast individual patient risk and guide tailored treatment plans. Researchers will also explore targeted nutritional interventions, both before and after transplant, to help mitigate deficiencies and enhance patient recovery.
The takeaway
This study highlights the importance of comprehensive patient assessment and personalized care approaches in multiple myeloma treatment. By closely monitoring factors like frailty and nutrition, healthcare providers can identify vulnerabilities and implement proactive strategies to optimize outcomes for each individual undergoing autologous stem cell transplantation.
